Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

Similar articles for PubMed (Select 22341852)

1.

Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.

Abdulahad WH, Kroese FG, Vissink A, Bootsma H.

J Autoimmun. 2012 Aug;39(1-2):103-11. doi: 10.1016/j.jaut.2012.01.009. Epub 2012 Feb 15. Review.

PMID:
22341852
2.

B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.

Cornec D, Devauchelle-Pensec V, Tobón GJ, Pers JO, Jousse-Joulin S, Saraux A.

J Autoimmun. 2012 Sep;39(3):161-7. doi: 10.1016/j.jaut.2012.05.014. Epub 2012 Jun 30. Review.

PMID:
22749831
3.

B-cell populations and sub-populations in Sjögren's syndrome.

Hamza N, Bos NA, Kallenberg CG.

Presse Med. 2012 Sep;41(9 Pt 2):e475-83. doi: 10.1016/j.lpm.2012.05.021. Epub 2012 Jul 26. Review.

PMID:
22841377
4.

Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.

Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA.

Ann Rheum Dis. 2012 Nov;71(11):1881-7. doi: 10.1136/annrheumdis-2011-201189. Epub 2012 May 21.

PMID:
22615459
5.

Pathophysiological cytokine network in primary Sjögren's syndrome.

Pers JO, Lahiri A, Tobón GJ, Youinou P.

Presse Med. 2012 Sep;41(9 Pt 2):e467-74. doi: 10.1016/j.lpm.2012.04.029. Epub 2012 Jul 24. Review.

PMID:
22836197
6.

Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.

Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X.

J Pathol. 2004 Apr;202(4):496-502.

PMID:
15095277
7.

Therapeutic potential for B-cell modulation in Sjögren's syndrome.

Mariette X.

Rheum Dis Clin North Am. 2008 Nov;34(4):1025-33, x. doi: 10.1016/j.rdc.2008.08.014. Review.

PMID:
18984420
8.

Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.

Hansen A, Lipsky PE, Dörner T.

Curr Opin Rheumatol. 2005 Sep;17(5):558-65. Review.

PMID:
16093833
9.

B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.

Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X.

Scand J Immunol. 2008 Feb;67(2):185-92. doi: 10.1111/j.1365-3083.2007.02049.x.

PMID:
18201372
10.

Anti-CD20 antibody in primary Sjögren's syndrome management.

Chen S, Liu Y, Shi G.

Curr Pharm Biotechnol. 2014;15(6):535-41. Review.

PMID:
25213362
11.

B cell-targeted therapies in Sjögren's syndrome.

Tobón GJ, Pers JO, Youinou P, Saraux A.

Autoimmun Rev. 2010 Feb;9(4):224-8. doi: 10.1016/j.autrev.2009.08.001. Epub 2009 Aug 9. Review.

PMID:
19671451
12.

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.

Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N, Sellam J, Lepajolec C, Mariette X.

Arthritis Res Ther. 2006;8(2):R51. Epub 2006 Feb 28.

13.

Role of B cells in Sjögren's syndrome--from benign lymphoproliferation to overt malignancy.

Jonsson R, Nginamau E, Szyszko E, Brokstad KA.

Front Biosci. 2007 Jan 1;12:2159-70. Review.

PMID:
17127453
14.

B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.

Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO.

Autoimmun Rev. 2010 Jul;9(9):604-8. doi: 10.1016/j.autrev.2010.05.006. Epub 2010 May 8. Review.

PMID:
20457281
15.

Primary Sjögren's syndrome and deficiency of ICA69.

Winer S, Astsaturov I, Cheung R, Tsui H, Song A, Gaedigk R, Winer D, Sampson A, McKerlie C, Bookman A, Dosch HM.

Lancet. 2002 Oct 5;360(9339):1063-9.

PMID:
12383988
16.

The future of B cell-targeted therapies in Sjögren's syndrome.

Cornec D, Saraux A, Devauchelle-Pensec V, Clodic C, Pers JO.

Immunotherapy. 2013 Jun;5(6):639-46. doi: 10.2217/imt.13.49. Review.

PMID:
23725286
17.

Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.

Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, Saraux A, Youinou P.

Arthritis Rheum. 2006 Jul;54(7):2280-8.

18.

Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, Gestermann N, Proust A, Lambotte O, Mariette X.

Ann Rheum Dis. 2007 Jun;66(6):790-7. Epub 2006 Dec 21.

19.

B-lymphocytes govern the pathogenesis of Sjögren's syndrome.

Youinou P, Saraux A, Pers JO.

Curr Pharm Biotechnol. 2012 Aug;13(10):2071-7. Review.

PMID:
22208653
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk